Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10733MR)

This product GTTS-WQ10733MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10733MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6395MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ13109MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ13397MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ7211MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ13906MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ15178MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA T1h
GTTS-WQ13116MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ2774MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW